Idorsia reports nine-month 2026 net loss of CHF 206 million, maintains full-year outlook

Idorsia reported a net loss of CHF 206 million for the first nine months of 2026, versus a CHF 34 million loss in the same period of 2025. Operating expenses were CHF 272 million, up CHF 20 million excluding prior-year one-off gains. The company maintained its full-year outlook, expecting Quviviq sales to reach CHF 200 million.

Detected & updated continuously · Source: Nebula